Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation

Nature Medicine

Volumn 10, Issue 8, 2004, Pages 849-857

  Araki, Toshiyuki ^a   Mohi, M Golam ^a   Ismat, Fraz A ^b   Bronson, Roderick T ^a   Williams, Ifor R ^c   Kutok, Jeffery L ^d   Yang, Wentian ^a   Pao, Lily I ^a   Gilliland, D Gary ^d   Epstein, Jonathan A ^e   Neel, Benjamin G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BIRTH DEFECT; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; EMBRYO; ENDOCARDIAL CUSHION DEFECT; FACE DYSMORPHIA; FLOW CYTOMETRY; GENE DOSAGE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; IMMUNOHISTOCHEMISTRY; LEUKEMIA; MOUSE; NONHUMAN; NOONAN SYNDROME; PRIORITY JOURNAL; SHORT STATURE;

ANIMALS; CELL LINEAGE; CRANIOFACIAL ABNORMALITIES; DISEASE MODELS, ANIMAL; ENDOCARDIAL CUSHION DEFECTS; FLOW CYTOMETRY; GENE DOSAGE; GENES, DOMINANT; HEART DEFECTS, CONGENITAL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, MUTANT STRAINS; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; MYELOPROLIFERATIVE DISORDERS; NOONAN SYNDROME; PRECIPITIN TESTS; PROTEIN-TYROSINE-PHOSPHATASE;

ANIMALIA;

EID: 4043056497     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1084     Document Type: Article

References (50)

1. Noonan, J.A. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am. J. Dis. Child. 116, 373-380 (1968).
2. Nora, J.J., Nora, A.H., Sinha, A.K., Spangler, R.D. & Lubs, H.A. The Ullrich-Noonan syndrome (Turner phenotype). Am. J. Dis. Child. 127, 48-55 (1974).
3. Allanson, J.E. Noonan syndrome. J. Med. Genet. 24, 9-13 (1987).
4. Noonan, J.A. Noonan syndrome. An update and review for the primary pediatrician. Clin. Pediatr. (Phila.) 33, 548-555 (1994).
5. Marino, B., Digilio, M.C., Toscano, A., Giannotti, A. & Dallapiccola, B. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J. Pediatr. 135, 703-706 (1999).
6. Marino, B. et al. Noonan syndrome: structural abnormalities of the mitral valve causing subaortic obstruction. Eur. J. Pediatr. 154, 949-952 (1995).
7. Digilio, M.C. et al. Noonan syndrome and aortic coarctation. Am. J. Med. Genet. 80, 160-162 (1998).
8. Bertola, D.R. et al. Cardiac findings in 31 patients with Noonan's syndrome. Arq. Bras. Cardiol. 75, 409-412 (2000).
9. Bader-Meunier, B. et al. Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J. Pediatr. 130, 885-889 (1997).
10. Johannes, J.M., Garcia, E.R., De Vaan, G.A. & Weening, R.S. Noonan's syndrome in association with acute leukemia. Pediatr. Hematol. Oncol. 12, 571-575 (1995).
11. Side, L.E. & Shannon, K.M. Myeloid disorders in infants with Noonan syndrome and a resident's "rule" recalled. J. Pediatr. 130, 857-859 (1997).
12. Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 29, 465-468 (2001).
13. Kosaki, K. et al. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J. Clin. Endocrinol. Metab. 87, 3529-3533 (2002).
14. Maheshwari, M. et al. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. Hum. Mutat. 20, 298-304 (2002).
15. Tartaglia, M. et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am. J. Hum. Genet. 70, 1555-1563 (2002).
16. Neel, B.G., Gu, H. & Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284-293 (2003).
17. Araki, T., Nawa, H. & Neel, B.G. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J. Biol. Chem. 278, 41677-41684 (2003).
18. Barford, D. & Neel, B.G. Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. Structure 6, 249-254 (1998).
19. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J. & Shoelson, S.E. Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450 (1998).
20. O'Reilly, A.M., Pluskey, S., Shoelson, S.E. & Neel, B.G. Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps. Mol. Cell. Biol. 20, 299-311 (2000).
21. Tartaglia, M. et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 34, 148-150 (2003).
22. Loh, M.L. et al. Somatic mutations in PTPN11 implicate the protein tyrosine phosphatase SHP-2 in leukemogenesis. Blood 103, 2325-2331 (2003).
23. Tartaglia, M. et al. Genetic evidence for lineage- and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 104, 307-313 (2004).
24. Musante, L. et al. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardiofacio-cutaneous syndrome. Eur. J. Hum. Genet. 11, 201-206 (2003).
25. Gitler, A.D. et al. Nf1 has an essential role in endothelial cells. Nat. Genet. 33, 75-79 (2003).
26. Ahmed, M.L. et al. Noonan's syndrome: abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr. Scand. 80, 446-450 (1991).
27. Jacks, T. et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 7, 353-361 (1994).
28. Brannan, C.I. et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 8, 1019-1029 (1994).
29. Lakkis, M.M. & Epstein, J.A. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125, 4359-4367 (1998).
30. Bahuau, M. et al. Exclusion of allelism of Noonan syndrome and neurofibromatosis-type 1 in a large family with Noonan syndrome- neurofibromatosis association. Am. J. Med. Genet. 66, 347-355 (1996).
31. Epstein, J.A. Developing models of DiGeorge syndrome. Trends Genet. 17, S13-S17 (2001).
32. Sarkozy, A. et al. Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes. J. Med. Genet. 40, 704-708 (2003).
33. Braun, B.S. et al. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl Acad. Sci. USA 101, 597-602 (2004).
34. Chan, I.T. et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113, 528-538 (2004).
35. Dieterlen-Lievre, F. Hematopoiesis: progenitors and their genetic program. Curr. Biol. 8, R727-R730 (1998).
36. Gitler, A.D. et al. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. Pediatr. Res. 55, 581-584 (2004).
37. Couly, G.F., Colley, P.M. & Le Douarin, N.M. The triple origin of skull in higher vertebrates: a study in quail-chick chimeras. Development 117, 409-429 (1993).
38. Koniges, G. & Lumsden, A. Rhombencephalic neural crest segmentation is preserved throughout craniofacial ontogeny. Development 122, 3229-3242 (1996).
39. Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915-925 (2003).
40. Ghosh, S. & Karin, M. Missing pieces in the NF-κB puzzle. Cell 109, S81-S96 (2002).
41. Kapoor, G.S., Zhan, Y., Johnson, G.R. & O'Rourke, D.M. Distinct domains in the SHP-2 prosphatase differentially regulate epidermal growth factor receptor/NF-κB activation through Gab1 in glioblastoma cells. Mol. Cell. Biol. 24, 823-836 (2004).
42. You, M., Flick, L.M., Yu, D. & Feng, G.S. Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J. Exp. Med. 193, 101-110 (2001).
43. Fragale, A., Tartaglia, M., Wu, J. & Gelb, B.D. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23, 267-277 (2004).
44. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
45. Itoh, M. et al. Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 20, 3695-3704 (2000).
46. Su, I.H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124-131 (2003).
47. Zhang, S.Q. et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13, 341-355 (2004).
48. Klaman, L.D. et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 20, 5479-5489 (2000).
49. Corson, L.B., Yamanaka, Y., Lai, K.M. & Rossant, J. Spatial and temporal patterns of ERK signaling during mouse embryogenesis. Development 130, 4527-4537 (2003).
50. Sattler, M. et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1, 479-492 (2002).